Meagan McFarland
Payments from drug & device makers
Across 82 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$425
- AstraZeneca$282
- Merck$242
- E.r. Squibb & Sons, L.L.C.$155
- AbbVie$136
- Exelixis Inc.$112
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,423100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $425 |
| AstraZeneca | 8 | $282 |
| Merck | 9 | $242 |
| E.r. Squibb & Sons, L.L.C. | 6 | $155 |
| AbbVie | 5 | $136 |
| Exelixis Inc. | 4 | $112 |
| Merz North America, Inc. | 1 | $96 |
| Sanofi | 3 | $82 |
| Pfizer | 4 | $82 |
| Novartis | 3 | $73 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Tersera Therapeutics LLC | 3 | $64 |
| Array Biopharma Inc | 3 | $57 |
| Incyte Corporation | 2 | $54 |
| Eisai Inc. | 2 | $54 |
| Springworks Therapeutics, Inc. | 1 | $43 |
| Coherus Oncology, Inc. | 1 | $41 |
| GSK | 2 | $40 |
| Agios Pharmaceuticals, Inc. | 1 | $40 |
| Gilead | 2 | $35 |
| Stemline Therapeutics Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Janssen Scientific Affairs, LLC | 2 | $28 |
| Tempus AI, Inc | 1 | $27 |
| Spectrum Pharmaceuticals Inc. | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Sobi, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,423 in reported general payments places this provider in the 90th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 12 | $20,917 |
| Oxycodone Hcl | 34 | $760 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $702 |
| Omeprazole | 39 | $497 |
| Tamsulosin Hcl | 11 | $472 |
| Finasteride | 16 | $431 |
| Cyclobenzaprine Hcl | 16 | $410 |
| Gabapentin | 19 | $382 |
| Lisinopril | 33 | $344 |
| Trazodone Hcl | 20 | $288 |
| Ondansetron OdtOndansetron | 26 | $285 |
| Atorvastatin Calcium | 30 | $272 |
| Prochlorperazine Maleate | 23 | $264 |
| Quetiapine Fumarate | 14 | $259 |
| Levothyroxine Sodium | 21 | $214 |
Paid to pharmacies, not to this prescriber.
Other family in Salem
- Kelli FarmSalem$16K
- Jennifer SmithSalem$7K
- Katelyn WilliamsSalem$6K
- Marsha NewellSalem$5K
- Christina O'GuinnSalem$3K
- Terry RomaniniSalem$3K
- Serena CaldwellSalem$3K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.